New study analyzes best donor match for AML stem cell transplants

NCT ID NCT07155382

Completed Knowledge-focused Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 98 adults with acute myeloid leukemia (AML) in first remission who received a stem cell transplant from a matched sibling, matched unrelated, or half-matched family donor. All patients got the same chemotherapy conditioning before transplant. Researchers tracked engraftment, graft-versus-host disease, infections, leukemia relapse, and survival to see how donor type and other factors influenced outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: busulfan, fludarabine, antithymocyte globulin
What this could lead to: If successful, this study could help doctors choose the best donor type and conditioning regimen for AML patients needing a stem cell transplant.
What could go wrong: This is an observational study, not a test of a new treatment. It cannot prove what works best, only suggest patterns. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.